User login
Update on Guidelines and Technology in the Diagnosis and Treatment of Trichomonas vaginalis
The Centers for Disease Control and Prevention (CDC) published an update to the Sexually Transmitted Diseases Treatment Guidelines in June 2015. This supplement covers the specific changes related to the diagnosis and treatment of Trichomonas vaginalis infection.
Click here to download the PDF.
Sharon L. Hillier, PhD
Professor
Departments of Obstetrics, Gynecology and
Reproductive Sciences and Microbiology
and Molecular Genetics
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Claire Danby, MD, MSc
Assistant Professor
Tufts University School of Medicine
Boston, Massachusetts
Department of Obstetrics and Gynecology
Maine Medical Center
Portland, Maine
Paul Nyirjesy, MD
Professor
Departments of Obstetrics and Gynecology and Medicine
Director, Drexel Vaginitis Center
Drexel University College of Medicine
Philadelphia, Pennsylvania
Maria Trent, MD, MPH
Associate Professor of Pediatrics
Division of General Pediatrics and Adolescent Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland
Disclosures: Dr. Hillier reports that she is a consultant to Perrigo and Symbiomix and has an ongoing relationship with Becton Dickinson, Cepheid, and Hologic. Dr. Danby reports no financial relationships relevant to this article. Dr. Nyirjesy reports that he is a consultant to Hologic and has received a research grant from Becton Dickinson. Dr. Trent reports that she is the Principal Investigator of an unrestricted research grant to Johns Hopkins University (employer) from Hologic, Inc.
The Centers for Disease Control and Prevention (CDC) published an update to the Sexually Transmitted Diseases Treatment Guidelines in June 2015. This supplement covers the specific changes related to the diagnosis and treatment of Trichomonas vaginalis infection.
Click here to download the PDF.
Sharon L. Hillier, PhD
Professor
Departments of Obstetrics, Gynecology and
Reproductive Sciences and Microbiology
and Molecular Genetics
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Claire Danby, MD, MSc
Assistant Professor
Tufts University School of Medicine
Boston, Massachusetts
Department of Obstetrics and Gynecology
Maine Medical Center
Portland, Maine
Paul Nyirjesy, MD
Professor
Departments of Obstetrics and Gynecology and Medicine
Director, Drexel Vaginitis Center
Drexel University College of Medicine
Philadelphia, Pennsylvania
Maria Trent, MD, MPH
Associate Professor of Pediatrics
Division of General Pediatrics and Adolescent Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland
Disclosures: Dr. Hillier reports that she is a consultant to Perrigo and Symbiomix and has an ongoing relationship with Becton Dickinson, Cepheid, and Hologic. Dr. Danby reports no financial relationships relevant to this article. Dr. Nyirjesy reports that he is a consultant to Hologic and has received a research grant from Becton Dickinson. Dr. Trent reports that she is the Principal Investigator of an unrestricted research grant to Johns Hopkins University (employer) from Hologic, Inc.
The Centers for Disease Control and Prevention (CDC) published an update to the Sexually Transmitted Diseases Treatment Guidelines in June 2015. This supplement covers the specific changes related to the diagnosis and treatment of Trichomonas vaginalis infection.
Click here to download the PDF.
Sharon L. Hillier, PhD
Professor
Departments of Obstetrics, Gynecology and
Reproductive Sciences and Microbiology
and Molecular Genetics
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Claire Danby, MD, MSc
Assistant Professor
Tufts University School of Medicine
Boston, Massachusetts
Department of Obstetrics and Gynecology
Maine Medical Center
Portland, Maine
Paul Nyirjesy, MD
Professor
Departments of Obstetrics and Gynecology and Medicine
Director, Drexel Vaginitis Center
Drexel University College of Medicine
Philadelphia, Pennsylvania
Maria Trent, MD, MPH
Associate Professor of Pediatrics
Division of General Pediatrics and Adolescent Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland
Disclosures: Dr. Hillier reports that she is a consultant to Perrigo and Symbiomix and has an ongoing relationship with Becton Dickinson, Cepheid, and Hologic. Dr. Danby reports no financial relationships relevant to this article. Dr. Nyirjesy reports that he is a consultant to Hologic and has received a research grant from Becton Dickinson. Dr. Trent reports that she is the Principal Investigator of an unrestricted research grant to Johns Hopkins University (employer) from Hologic, Inc.
Highlights From the SCNS Meeting
Click here to download the digital edition.
Click here to download the digital edition.
Click here to download the digital edition.
Rare Neurological Disease Special Report
Click here to visit the digital edition.
Click here to visit the digital edition.
Click here to visit the digital edition.
Hereditary Cancer Testing in a Value Based World: The Evolving Standard of Care
Commemorating the 20th anniversary of BRCA genetic testing, we are increasingly conscious of the social, economic, and medico-legal impacts of genetic cancer risk on both personal and public health. An ever-growing number of medical societies and expert panels have now charged clinicians with the duty to evaluate and manage their patients’ cancer risk profiles, with particular attention to those individuals carrying genetic mutations that confer elevated cancer susceptibility, a process commonly known as hereditary cancer risk assessment, or HCRA.
Click here to download the PDF.
This article is written for women’s health care clinicians, and will address the current status of hereditary cancer genetic testing, focusing on the evolution of pan-cancer, multigene panel testing in the context of value-based medicine.
Click on the video below to watch Dr. Frieder discuss Hereditary Cancer Testing.
Commemorating the 20th anniversary of BRCA genetic testing, we are increasingly conscious of the social, economic, and medico-legal impacts of genetic cancer risk on both personal and public health. An ever-growing number of medical societies and expert panels have now charged clinicians with the duty to evaluate and manage their patients’ cancer risk profiles, with particular attention to those individuals carrying genetic mutations that confer elevated cancer susceptibility, a process commonly known as hereditary cancer risk assessment, or HCRA.
Click here to download the PDF.
This article is written for women’s health care clinicians, and will address the current status of hereditary cancer genetic testing, focusing on the evolution of pan-cancer, multigene panel testing in the context of value-based medicine.
Click on the video below to watch Dr. Frieder discuss Hereditary Cancer Testing.
Commemorating the 20th anniversary of BRCA genetic testing, we are increasingly conscious of the social, economic, and medico-legal impacts of genetic cancer risk on both personal and public health. An ever-growing number of medical societies and expert panels have now charged clinicians with the duty to evaluate and manage their patients’ cancer risk profiles, with particular attention to those individuals carrying genetic mutations that confer elevated cancer susceptibility, a process commonly known as hereditary cancer risk assessment, or HCRA.
Click here to download the PDF.
This article is written for women’s health care clinicians, and will address the current status of hereditary cancer genetic testing, focusing on the evolution of pan-cancer, multigene panel testing in the context of value-based medicine.
Click on the video below to watch Dr. Frieder discuss Hereditary Cancer Testing.
2015 MS Highlights: The Year in Review
Click here to download the PDF.
Click here to download the PDF.
Click here to download the PDF.
Antiepileptic Drugs and Hyponatremia
2016 Directory of VA and DoD Facilities
Click here to access the 2016 Directory of VA and DoD Facilities Digital Edition
Table of Contents
- Letter From the Publisher
- Explanatory Notes and Abbreviation Key
- Veterans Integrated Service Network (VISN) Guide / MyVA Regions Guide
- Department of Veterans Affairs Health Care Facilities
- TRICARE Region Guide
- Department of Defense Health Care Facilities
Click here to access the 2016 Directory of VA and DoD Facilities Digital Edition
Table of Contents
- Letter From the Publisher
- Explanatory Notes and Abbreviation Key
- Veterans Integrated Service Network (VISN) Guide / MyVA Regions Guide
- Department of Veterans Affairs Health Care Facilities
- TRICARE Region Guide
- Department of Defense Health Care Facilities
Click here to access the 2016 Directory of VA and DoD Facilities Digital Edition
Table of Contents
- Letter From the Publisher
- Explanatory Notes and Abbreviation Key
- Veterans Integrated Service Network (VISN) Guide / MyVA Regions Guide
- Department of Veterans Affairs Health Care Facilities
- TRICARE Region Guide
- Department of Defense Health Care Facilities
Abstracts Presented at the 2015 AVAHO Annual Meeting
An Update on the Diagnosis and Treatment of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic, inflammatory, scarring disease that occurs most frequently along the milk lines of the body from axillae to groin, is most common in the second and third decades of life, and is rarely observed before puberty. It disproportionately affects women and is associated with a host of comorbidities and dramatically reduced quality of life. The delay from HS symptom onset to diagnosis is approximately 7 years, with drastic consequences for patient well being. Early diagnosis and treatment are of paramount importance. While several nonpharmacologic, pharmacologic, and surgical treatment modalities exist for HS, only one agent, adalimumab, has been approved by the US Food and Drug Administration for this indication. Lifestyle modifications, dietary changes, patient education, and psychosocial support are important components of HS therapy.
Hidradenitis suppurativa (HS) is a chronic, inflammatory, scarring disease that occurs most frequently along the milk lines of the body from axillae to groin, is most common in the second and third decades of life, and is rarely observed before puberty. It disproportionately affects women and is associated with a host of comorbidities and dramatically reduced quality of life. The delay from HS symptom onset to diagnosis is approximately 7 years, with drastic consequences for patient well being. Early diagnosis and treatment are of paramount importance. While several nonpharmacologic, pharmacologic, and surgical treatment modalities exist for HS, only one agent, adalimumab, has been approved by the US Food and Drug Administration for this indication. Lifestyle modifications, dietary changes, patient education, and psychosocial support are important components of HS therapy.
Hidradenitis suppurativa (HS) is a chronic, inflammatory, scarring disease that occurs most frequently along the milk lines of the body from axillae to groin, is most common in the second and third decades of life, and is rarely observed before puberty. It disproportionately affects women and is associated with a host of comorbidities and dramatically reduced quality of life. The delay from HS symptom onset to diagnosis is approximately 7 years, with drastic consequences for patient well being. Early diagnosis and treatment are of paramount importance. While several nonpharmacologic, pharmacologic, and surgical treatment modalities exist for HS, only one agent, adalimumab, has been approved by the US Food and Drug Administration for this indication. Lifestyle modifications, dietary changes, patient education, and psychosocial support are important components of HS therapy.
Cardiovascular Disease: From Milestones to Innovations
Supplement Editor:
Maan A. Fares, MD
Contents
Introduction: The transition from milestones to innovations
Maan a. Fares, MD
Transcatheter aortic valve replacement: History and current indications
Ahmad Zeeshan, MD; E. Murat Tuzcu, MD; Amar Krishnaswamy, MD; Samir Kapadia, MD; and Stephanie Mick, MD
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation
Ayman Hussein, MD; Walid Saliba, MD; and Oussama Wazni, MD
Stroke management and the impact of mobile stroke treatment units
Peter A. Rasmussen, MD
Biomarkers: Their potential in the diagnosis and treatment of heart failure
Barbara Heil, MD, and W.H. Wilson Tang, MD
Clinical challenges in diagnosing and managing adult hypertension
Joel Handler, MD
Supplement Editor:
Maan A. Fares, MD
Contents
Introduction: The transition from milestones to innovations
Maan a. Fares, MD
Transcatheter aortic valve replacement: History and current indications
Ahmad Zeeshan, MD; E. Murat Tuzcu, MD; Amar Krishnaswamy, MD; Samir Kapadia, MD; and Stephanie Mick, MD
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation
Ayman Hussein, MD; Walid Saliba, MD; and Oussama Wazni, MD
Stroke management and the impact of mobile stroke treatment units
Peter A. Rasmussen, MD
Biomarkers: Their potential in the diagnosis and treatment of heart failure
Barbara Heil, MD, and W.H. Wilson Tang, MD
Clinical challenges in diagnosing and managing adult hypertension
Joel Handler, MD
Supplement Editor:
Maan A. Fares, MD
Contents
Introduction: The transition from milestones to innovations
Maan a. Fares, MD
Transcatheter aortic valve replacement: History and current indications
Ahmad Zeeshan, MD; E. Murat Tuzcu, MD; Amar Krishnaswamy, MD; Samir Kapadia, MD; and Stephanie Mick, MD
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation
Ayman Hussein, MD; Walid Saliba, MD; and Oussama Wazni, MD
Stroke management and the impact of mobile stroke treatment units
Peter A. Rasmussen, MD
Biomarkers: Their potential in the diagnosis and treatment of heart failure
Barbara Heil, MD, and W.H. Wilson Tang, MD
Clinical challenges in diagnosing and managing adult hypertension
Joel Handler, MD
